CMS Endorses Combined Pap/HPV Testing, Piper Jaffray Notes (HOLX) (QGEN) (BDX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Piper Jaffray Maintains a Neutral Rating on Qiagen (QGEN) Following Expanded Channel Checks
July 14, 2015 8:02 AM EDTPiper Jaffray maintains a Neutral rating and $24.00 price target on Qiagen NV (NASDAQ: QGEN) following expanded channel checks. Analyst William Quirk says that the latest checks did not uncover additional transitions from Qiagen to alternative HPV platforms, and views this as a sighn that shares are stabilizing.
Quirk commented,... More
Piper Jaffray Downgrades Hologic (HOLX) to Neutral
July 14, 2015 6:36 AM EDTPiper Jaffray downgraded Hologic (NASDAQ: HOLX) from Overweight to Neutral with a price target of $38.00 on valuation.
Analyst William Quirk commented, "Our fundamental turnaround thesis on Hologic remains intact, however, with HOLX shares trading north of 20x FY16E, we believe shares... More
